23rd - 24th September, 2026 | Berlin, Germany

www.lipid-nanoparticle-development-europe.com

SAVE €500 BY REGISTERING BEFORE FRIDAY, 5TH JUNE

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

5th Annual

Lipid Nanoparticles Development Summit EUROPE

Unleashing LNP Innovation for Safe, Selective & Stable Drug Delivery

Spearheading End-to-End LNP Development by Leveraging Novel Lipids, Incorporating Automation & Improving Reliability of Analytics to Accelerate LNPs from Research to Market

Expert Speakers Include:

Alexander Kros
Full Professor
Leiden University

Ansgar Santel
Chief Executive Officer
Pantherna Therapeutics

Roy Pattipeiluhu
Director, Early-Stage Formulation Process Development, LNP Technology
BioNTech

Panagiota Papadopoulou
Marie Skłodowska-Curie Postdoctoral Fellow
National Hellenic Research Foundation

Shilpkala Gade
Higher Scientist
MHRA

Suzanne SaffieSiebert
Chief Executive Officer
SiSaf

Proud to Partner With:

UNCHAINED LABS ARDENA nanofcm PARTICLE METRIX

+44 (0)20 3141 8700 info@hansonwade.com

www.lipid-nanoparticle-development-europe.com LNP Development Event Series

hansonwade

Welcome to the 5th Lipid Nanoparticles Development Summit Europe

5th Annual Lipid Nanoparticles Development Summit

23rd - 24th September, 2026 | Berlin, Germany

The **5th Lipid Nanoparticles Development Summit Europe** arrives in Berlin this September as Europe's established, go-to meeting for the LNP community. The 2026 summit will provide **comprehensive**, **end-to-end technical content** spanning analytical development, formulation optimisation and scalable manufacturing strategies to accelerate safe, efficient and specific delivery across a broad range of payloads, including mRNA, DNA, siRNA, cell, and gene therapies.

Despite rapid progress, the LNP community continues to face shared challenges in **formulation stability**, **large-scale manufacturing**, **extrahepatic targeting** and **reliable**, **robust analytics**. Hence, this forum provides a critical opportunity to connect and unite with fellow LNP experts to exchange data-driven insights and refine delivery strategies to enable the continued evolution and progression of efficacious LNP platforms.

Built with insights from leading innovative biopharma including **Johnson & Johnson**, **Sanofi**, **AbbVie**, **BioNTech** and more, this summit is designed for LNP discovery, formulation, R&D, analytical and process development experts seeking actionable strategies to accelerate LNPs from research to market.

What Our Speakers Have to Say

"The summit provided an excellent opportunity to understand the latest advancements in lipid nanoparticle design and formulation. I especially appreciated the balance between academic insights and industry case studies"

Research Fellow, Development Centre for Biotechnology

Skills & Insights You'll Walk Away With

Master end-to-end LNP development, from early formulation design through to analytical characterisation, CMC strategy and scalable manufacturing, ensuring you can move programs from concept to clinic with confidence

Uncover strategies to overcome liver tropism and enable true extrahepatic delivery, with deep dives into biodistribution control, cell-specific targeting and emerging approaches to access complex tissues like the brain and lungs

Learn how to balance potency, safety and repeat dosing, including tackling immunogenicity, anti-PEG responses and toxicity challenges to improve therapeutic durability and clinical viability

Translate cutting-edge LNP innovation into real-world applications, with insights spanning mRNA, DNA, siRNA, gene editing and next-generation hybrid systems across multiple therapeutic areas

Engage in highly interactive formats including debates, roundtables and simulation exercises, enabling you to benchmark strategies, challenge assumptions and gain practical insights from industry leaders and peers

What's New for 2026?

Engineer Smarter LNPs for Extrahepatic Delivery: Join the conference and focus on achieving cell-specific targeting through ligand conjugation and surface chemistry redesign, moving beyond liver accumulation toward brain, lung and tumor applications

Dive into Hybrid & Next-Generation LNP Systems: Explore how polymer-free, peptide and hybrid lipid technologies are simplifying formulation, improving safety and expanding LNP use across mRNA, srRNA and gene-editing modalities with new insights from **BioNTech**, **AstraZeneca** and **Pantherna Therapeutics**

Gain Unparalleled Analytical & Regulatory Depth: 2026 adds a full track on single-particle characterisation, quality by design integration and phase-appropriate CMC decision-making, featuring practical sessions led by experts from **AbbVie** and **MHRA**

Debate What Will Truly Break Liver Tropism: An all-new interactive discussion pits leading voices from **Abogen**, **Leiden University** and **Pantherna Therapeutics** against one another to determine which strategy, lipid chemistry, ligand targeting or hybrid design, will finally enable viable extrahepatic delivery

Expand Your View from Bench to Commercialisation: This year's sessions go further into manufacturability and scalability, tackling hybrid-LNP process control, GMP reproducibility and IP strategy to help teams bridge the gap from innovative design to regulatory-ready clinical translation

The 2026 edition marks a shift from foundational LNP formulation and stability toward real-world translation, integrating design, analytics and regulation for next-generation therapeutic delivery systems.

+44 (0)20 3141 8700 info@hansonwade.com
www.lipid-nanoparticle-development-europe.com LNP Development Event Series
hansonwade

What's New For 2026?

5th Annual Lipid Nanoparticles Development Summit EUROPE
23rd - 24th September, 2026 | Berlin, Germany

Key Sessions Not to Miss

1 Developing Polymer-Free Lipid Nanoparticles to Simplify Formulation & Improve Safety & Manufacturability of mRNA Delivery: Roy Pattipeiluhu (BioNTech)

Don't miss this session to understand how polymer-free LNP systems can simplify formulation while improving safety, scalability and manufacturability for next-generation mRNA delivery

2 Improve Stability, Storage & Formulation to Support Real-World Use: Shilpkala Gade (MHRA)

Gain critical insight into how stability, storage and real-world deployment considerations align with regulatory expectations and impact clinical and commercial success

3 Visualising & Engineering Intracellular LNP Behaviour: Unlocking Endosomal Escape & Cell-Specific Targeting: Panagiota Papadopoulou (National Hellenic Research Foundation)

Discover how advanced cryo-EM imaging is unlocking intracellular LNP behaviour to better understand endosomal escape and enable more precise, cell-specific targeting

4 Engineering LNPs for Next Generation Vaccines & Therapeutics: Heinrich Haas (NeoVac)

Learn how rational LNP design is being translated into clinically validated systems with improved safety, reduced reactogenicity and potential for repeat dosing

5 Understand & Overcome Liver Tropism to Enable Extrahepatic Delivery: Ansgar Santel (Pantherna Therapeutics)

Explore cutting-edge strategies to overcome liver tropism and drive extrahepatic delivery, tackling one of the biggest barriers to unlocking broader therapeutic applications of LNPs

New Companies for 2026

AstraZeneca | ABOGEN 艾博生物 | Cyberna 星辰智曜 | Medicines & Healthcare products Regulatory Agency | Pantherna Therapeutics

Showcase Your Scientific Poster

Contribute to the conversation and share your cutting-edge research with your fellow LNP community to showcase your breakthrough discoveries to a vast audience of experts.

Register your place to submit an abstract for review to showcase your poster.
Please visit the event website for full T&Cs.

+44 (0)20 3141 8700 info@hansonwade.com
www.lipid-nanoparticle-development-europe.com LNP Development Event Series
hansonwade

Your Expert Speakers

Ansgar Santel
Chief Executive Officer
Pantherna Therapeutics

Suzanne SaffieSiebert
Chief Executive Officer
SiSaf

Roy Pattipeiluhu
Director, Early-Stage Formulation Process Development, LNP Technology
BioNTech

Panagiota Papadopoulou
Marie Skłodowska-Curie Postdoctoral Fellow
National Hellenic Research Foundation

Heinrich Haas
Chief Technology Officer
NeoVac

Chuan-En Lu
Senior Scientist, Process Analytical Technology, Global Medicines Development
AstraZeneca

Dan Shores
Partner
Rothwell Figgs

Alexander Kros
Full Professor
Leiden University

Mengjie Shen
Scientist
Abogen Biosciences

Kamalinder Kaur Singh
Chair in Pharmaceutical Technology & Drug Delivery
School of Pharmacy & Biomedical Sciences, University of Central Lancashire

Mahdi Zeraati
Cancer Institute Fellow
University of Sydney

Pengbo Guo
Head of Product Development
CybernaX Biotechnologies

Shilpkala Gade
Higher Scientist
MHRA

Gholan Hamraz
PhD Candidate
BioNTech

Janos Szebeni
Group Head at the Department of Translational Medicine
Semmelweis University

Maria Irujo
Formulation & Pharmaceutical Innovation
Advanced BioDesign

"Participants can attend expert-led sessions and workshops, enabling them to enhance their understanding and application of LNPs in drug delivery and therapeutic development. This summit will be a valuable opportunity to stay at the forefront of LNP research and development, fostering collaboration and accelerating progress in the field."

Senior Vice President, CureVac

Conference Day One
Wednesday, 23rd September

8.00 **Check-In & Coffee**

8.50 **Chair's Opening Remarks**

Advance Next Generation & Hybrid LNP Systems into Real Clinical Applications

9.00 **Introductory Panel: Identify Which LNP Applications Will Deliver Clinical & Commercial Success Across Emerging Modalities**

A cross-disciplinary panel bringing together leaders working across the most advanced and emerging applications of LNP delivery, including srRNA, gene editing, *in vivo* cell therapy, oncology, autoimmune disease and protein replacement.

- Compare delivery requirements across different therapeutic modalities
- Identify where LNPs are already working vs where they are still failing
- Understand how application choice impacts design, toxicity and manufacturability
- Evaluate which areas are overhyped vs commercially viable
- Explore how hybrid systems (lipids, polymers, peptides) are expanding capability

Ansgar Santel
Chief Executive Officer
Pantherna Therapeutics

Suzanne SaffieSiebert
Chief Executive Officer
SiSaf

Roy Pattipeiluhu
Director, Early-Stage Formulation Process Development, LNP Technology
BioNTech

10.00 **Developing Polymer-Free Lipid Nanoparticles to Simplify Formulation & Improve Safety & Manufacturability of mRNA Delivery**

- Evaluate the role of polymers in LNP systems, identify sources of added complexity and toxicity and redesign formulations to maintain performance while simplifying composition
- Optimise lipid-only formulations, improve encapsulation efficiency and delivery performance, reduce variability and enhance manufacturability
- Assess the impact of polymer-free systems on safety, immunogenicity and scalability, enable more robust and clinically viable mRNA delivery platforms

10.30 **Reserved session for Nano FCM**

10.40 **Morning Break & Speed Networking**
As this community unites, this session will provide valuable networking time with your peers, enabling you to forge new and lasting connections.

Panagiota Papadopoulou
Marie Skłodowska-Curie Postdoctoral Fellow
National Hellenic Research Foundation
NEW COMPANY

11.40 **Visualising & Engineering Intracellular LNP Behaviour: Unlocking Endosomal Escape & Cell-Specific Targeting**

- Map intracellular LNP structure and integrity using advanced cryo-EM imaging
- Investigate endosomal escape mechanisms under physiologically relevant conditions
- Link nanoparticle morphology and phase behavior to cell-specific targeting outcomes
- Generate early *in vitro* and *in vivo* insights to inform rational LNP design beyond trial-and-error

Heinrich Haas
Chief Technology Officer
NeoVac

12.00 **Engineering LNPs for Next Generation Vaccines & Therapeutics**

- Rational design approaches are applied for tailoring lipid and LNP architecture
- Tailored formulations with tunable immunogenicity and precise targeting specificity are provided
- Formulations allow for repeat dosing in therapeutic settings
- Improved safety and reduced reactogenicity were demonstrated in a clinical study

Conference Day One
Wednesday, 23rd September

12.30 **Lunch Break & Networking**

Build Analytical & QC Strategies That Enable Reliable & Regulatory Ready LNP Development

Chuan-En Lu
Senior Scientist, Process Analytical Technology, Global Medicines Development
AstraZeneca
NEW COMPANY

1.30 **Characterise LNP Heterogeneity Using Single Particle & Advanced Analytical Techniques**

- Apply single particle methods, reveal hidden variability and improve formulation understanding
- Compare analytical platforms, select appropriate tools and increase data reliability
- Link particle heterogeneity, predict performance and reduce development risk

Dan Shores
Partner
Rothwell Figgs
NEW COMPANY
VIRTUAL

2.00 **Navigate the Patent Landscape to Protect Innovation & Avoid Development Risk**

- Analyse patent trends, identify freedom to operate and reduce legal risk
- Evaluate academic outputs, identify commercial potential and guide investment decisions
- Structure IP strategy, protect innovation and enhance company value

Integrate Innovation CMC & Regulatory Strategy to Accelerate LNPs into the Clinic

2.30 **Roundtable: Understand What Regulators Expect & Apply Strategies to Accelerate Approval**

A practical, discussion-led session where participants work through real regulatory scenarios, aligning analytical, CMC and development strategies with phase-appropriate expectations to accelerate clinical progression.

- Clarify what "phase-appropriate" development really means in practice
- Identify where teams over-engineer and over-characterise LNP systems
- Understand how to prioritise critical data vs nice-to-have data
- Align analytical, CMC and clinical strategies with regulatory expectations
- Reduce delays caused by misaligned development strategies

3.00 **Afternoon Break & Poster Session**

This is your opportunity to contribute to the conversation and share your cutting-edge research with this community while discovering exciting work carried out by your peers. To submit a poster, please contact info@hansonwade.com.

4.00 **Closing Simulation Exercise: Work Through Real World Scenarios to Successfully Take an LNP Therapy from Concept to Clinic**

A practical, end-to-end simulation where participants work through the full lifecycle of an LNP therapy, integrating innovation, CMC and regulatory decision-making to successfully move a candidate toward clinical readiness.

- A practical framework for evaluating LNP designs beyond scientific performance
- Clear understanding of how CMC and regulatory constraints reshape innovation
- Improved ability to make phase-appropriate decisions that accelerate timelines
- Real insight into where most LNP programs fail or stall before clinic

Roy Pattipeiluhu
Director Early-Stage Formulation Process Development, LNP Technology
BioNTech

Panagiota Papadopoulou
Marie Skłodowska-Curie Postdoctoral Fellow
National Hellenic Research Foundation

ARDENA

5.00 **Chair's Closing Remarks**

5.15 **End of Conference Day One**

Conference Day Two
Thursday, 24th September

8.00 **Check-In & Coffee**

8.50 **Chair's Opening Remarks**

Achieving Precise Targeting & Efficient Delivery Beyond the Liver

Ansgar Santel
Chief Executive Officer
Pantherna Therapeutics
NEW COMPANY

9.00 **Understand & Overcome Liver Tropism to Enable Extrahepatic Delivery**

- Analyse biodistribution mechanisms and drivers of liver accumulation
- Modify lipid structure and formulation parameters to shift organ targeting
- Validate targeting strategies *in vivo* to strengthen translational confidence

Alexander Kros
Full Professor
Leiden University

9.30 **Achieving Cell-Specific LNP Delivery & BBB Penetration for Complex Diseases**

- Explore strategies to modulate LNP composition and surface characteristics to enable selective targeting beyond hepatic tissues and improve cell-specific uptake
- Assess emerging approaches to overcome biological barriers, including the blood–brain barrier, to unlock delivery to previously inaccessible tissues
- Evaluate how advances in targeting, biodistribution control and *in vivo* performance are translating into more effective therapies for complex and hard-to-treat diseases

Mengjie Shen
Scientist
Abogen Biosciences
NEW COMPANY

10.00 **Rational Design of Lipid Nanoparticle for mRNA Target Delivery**

- Optimise lipid composition and formulation parameters to improve mRNA delivery efficiency, stability and safety
- Tune LNP design to influence biodistribution and enable more precise, cell-specific targeting
- Bridge discovery and clinical translation by aligning LNP design with scalability, manufacturability and regulatory requirements

10.30 **Morning Break & Networking**

11.30 **Debate: Which Strategy Will Truly Break Liver Tropism & Enable Clinically Viable Extrahepatic Delivery**

3–4 speakers each briefly defend a different approach in this open debate. The audience votes on the most promising strategy.

- Lipid chemistry vs formulation tuning vs hybrid systems
- Passive biodistribution control vs active targeting (ligands, peptides, etc.)
- Incremental optimisation vs completely new delivery paradigms
- What actually translates *in vivo* vs what only works in preclinical models

Mengjie Shen
Scientist
Abogen Biosciences

Alexander Kros
Full Professor
Leiden University

Maria Irujo
Formulation & Pharmaceutical Innovation
Advanced BioDesign

Ansgar Santel
Chief Executive Officer
Pantherna Therapeutics

Mahdi Zeraati
Cancer Institute Fellow
University of Sydney
NEW COMPANY

12.00 **End-User Perspectives: Translating LNP Design into Therapeutic Reality**

- Evaluate how LNP design choices impact therapeutic performance in real disease models
- Identify gaps between delivery optimisation and clinical application needs
- Assess how researchers adapt existing LNP platforms for specific therapeutic use cases
- Highlight where current LNP systems fall short from an end-user perspective

Conference Day Two
Thursday, 24th September

12.30 **Lunch Break & Networking**

Reduce Toxicity Enable Repeat Dosing & Improve Therapeutic Durability

Pengbo Guo
Head of Product Development
CybernaX Biotechnologies
NEW COMPANY

1.30 **Beyond PEGylation: Engineering Novel PEG-Alternatives to Mitigate Anti-PEG Responses & Enable Repeatable LNP Delivery**

- Bypassing accelerated blood clearance by reducing recognition from pre-existing and induced anti-PEG antibodies
- Structural design of PEG-alternatives that maintain nanoparticle stability and endosomal escape while minimising immune detection
- Reviewing *in vivo* and NHP data demonstrating sustained protein expression and low toxicity across longitudinal dosing cycles

Janos Szebeni
Group Head at the Department of Translational Medicine
Semmelweis University
NEW COMPANY

2.00 **mRNA–LNP COVID-19 Vaccines: Insights from Conventional Immunisation & Drug-Targeting Principles**

- Applying drug-targeting and immunisation principles to reduce off-target toxicity and improve tolerability of mRNA–LNP vaccines
- Designing formulations and dosing strategies that enable safe repeat administration without diminishing immune response
- Optimising LNP composition and delivery to enhance therapeutic durability and sustain protective efficacy over time

2.30 **Afternoon Break & Networking**

Enhance Stability, Storage & Real-World Deployability of LNP Systems

Shilpkala Gade
Higher Scientist
MHRA
NEW COMPANY

3.00 **Improve Stability Storage & Formulation to Support Real World Use**

- Evaluate degradation pathways, optimise formulation stability and extend shelf life
- Improve thermostability, reduce cold chain dependency and enable broader distribution
- Align storage conditions with performance requirements and ensure reliability in clinical and commercial settings

Kamalinder Kaur Singh
Chair in Pharmaceutical Technology & Drug Delivery
University of Central Lancashire

3.30 **Precision Inhaled siRNA Therapies: Advancing Targeted Gene Silencing for Next-Generation Respiratory Medicine**

- Exploring the design and delivery of inhaled siRNA therapies for targeted, tissue-specific gene silencing
- Overcoming key challenges in pulmonary delivery, stability and efficient cellular uptake
- Translating preclinical innovation into clinical success for precision respiratory therapeutics

ARDENA

4.00 **Chair's Closing Remarks**

4.15 **End of Conference Day Two**

2026 Partners

Innovation Partner - Nano FCM

NanoFCM specializes in high-sensitivity flow cytometry solutions designed for the analysis of nanoscale biological particles, such as exosomes, viruses, and nanoparticles. Their proprietary Nano-Flow Cytometry (nFCM) platform enables precise sizing, counting, and phenotyping at the single-particle level, supporting advanced research in drug delivery, diagnostics, and nanomedicine.

www.nanofcm.com

Exhibition Partner - Particle Metrix

Particle Metrix is a technology company specializing in advanced nanoparticle analysis solutions using nanoparticle tracking analysis (NTA). Their high-precision instruments, such as the ZetaView® platform, enable researchers to measure particle size, concentration, and surface charge at the nanoscale, supporting applications across biotechnology, pharmaceuticals, nanomedicine, and materials science.

www.particle-metrix.com

Exhibition Partner - Unchained Labs

Unchained Labs is a life sciences tools company that develops innovative instruments and automation solutions for biologics and gene therapy researchers. Their platforms help scientists analyze, characterize, and optimize complex molecules, supporting processes such as protein stability testing, nucleic acid quantification, and nanoparticle characterization, while streamlining workflows and accelerating drug development.

www.unchainedlabs.com

Event Partner - Ardena Holding NV

Ardena is a global contract development and manufacturing organization (CDMO) that supports pharmaceutical and biotech companies in bringing innovative therapies to market. Through an integrated platform spanning drug substance development, formulation, manufacturing, bioanalysis, and regulatory support, Ardena helps accelerate complex drug development programs from early-stage research through to clinical trials and commercialization.

www.ardena.com

Get Involved



Maddie Woodside
Partnership Director
Tel: +44 (0)20 3141 8700
Email: sponsor@hansonwade.com

Take the Spotlight & Partner with Leading & Emerging Lipid Nanoparticle Innovators

5th Annual Lipid Nanoparticles Development Summit EUROPE
23rd - 24th September, 2026 | Berlin, Germany

The leading European meeting place to forge new partnerships and strengthen collaborations across the rapidly advancing LNP field

Position Yourself at the Forefront of LNP Innovation

Reinforce and elevate your position within the rapidly advancing LNP space by showcasing your expertise across formulation, delivery, analytics and manufacturing. With a faculty spanning leading biopharma, biotech and regulatory bodies, this is your opportunity to align your brand with cutting-edge science and position yourself as a key player driving the next generation of nucleic acid therapeutics

Gain Early Insight into the Next Wave of LNP Development

Access exclusive, forward-looking insights into the strategies shaping the future of LNPs, from overcoming liver tropism and enabling extrahepatic delivery to improving stability, reducing toxicity and advancing hybrid systems. Through expert-led sessions, panels and interactive discussions, stay ahead of emerging trends, technological breakthroughs and shifting industry priorities

Unlock High-Value Commercial Opportunities with a Targeted Audience

Engage directly with a highly curated audience of decision-makers across pharma, biotech and academia, all actively working to advance LNP therapeutics. With built-in networking sessions, workshops and interactive formats, this summit provides a focused environment to initiate partnerships, generate leads and accelerate meaningful collaborations at a critical time for the field

Seniority of Attendees



- C-level: 14%
- Vice Presidents: 4%
- Directors: 12%
- Managers: 9%
- Senior Scientists: 32%
- Others: 29%

Type of Companies Attending



*Statistics Taken from 4th Lipid Nanoparticle Development Summit Europe

Get Involved



Maddie Woodside
Partnership Director
Tel: +44 (0)20 3141 8700
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.lipid-nanoparticle-development-europe.com/register

Tel: +44 (0)20 3141 8700

Email: info@hansonwade.com

DISCOVER how leading pharma and biotech organisations are advancing next-generation LNP systems, from achieving extrahepatic delivery and cell-specific targeting to engineering novel lipid chemistries, hybrid nanoparticles and platform innovations across mRNA, gene editing and emerging modalities.

BUILD a deeper understanding of the key scientific, translational and CMC challenges shaping LNP development, including overcoming liver tropism, improving biodistribution and targeting accuracy, managing toxicity and immunogenicity and aligning analytical, manufacturing and regulatory strategies to successfully reach the clinic.

ENGAGE with a highly specialised global community of LNP experts across biopharma, academia and technology providers to exchange insights, benchmark strategies and form meaningful collaborations that accelerate the development of safe, effective and commercially viable nanoparticle-based therapeutics.

Drug Developer Pricing*	Register & Pay By Friday, 5th June	On the Door Price
Conference Only	€1,999 **(Save €500)**	€2,499

Academic & Small Biotech Pricing**	Register & Pay By Friday, 5th June	On the Door Price
Conference Only	€1,599 **(Save €500)**	€2,099

Solution & Service Provider Pricing	Register & Pay By Friday, 5th June	On the Door Price
Conference Only	€2,599 **(Save €500)**	€3,099

*To qualify for the drug developer rate your company must have a public drug pipeline and not provide fee-based services.

**To qualify for academic and research rate you must be full time academic. To qualify for the small biotech rate, your company must have fewer than 200 employees or have been established no more than 5 years ago.

Do you work for a Not-for-Profit organisation? Email us at info@hansonwade.com to inquire about attending

If you are a UK or EU-based company, you may be subject to 19% VAT in addition to the price advertised. If you qualify for a reverse charge, you will have the option to provide your VAT number and the charge will be automatically deducted at checkout.

Please visit the website for full pricing options or email info@hansonwade.com

Team Discounts***

- **10% discount – 2 Attendees**
- **15% discount – 3 Attendees**
- **20% discount – 4+ Attendees**

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: info@hansonwade.com

Venue

Dorint Kurfürstendamm Berlin
Augsburger Strasse 41, Berlin, Germany, 10789
www.hotel-berlin.dorint.com/en/

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade Conferences Limited is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Conferences Limited, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom